NCT05093608View on ClinicalTrials.gov

SELINEXOR in Combination w/Bevacizumab and Atezolizumab in Newly Diagnosed Advanced Hepatocellular Carcinoma

PHASE1TerminatedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

November 3, 2021

Primary Completion Date

October 12, 2022

Study Completion Date

October 12, 2022

Conditions
Hepatocellular Carcinoma
Interventions
DRUG

Selinexor Pill

Selinexor 60 mg or 80 mg (oral table) will be administered once a week.

DRUG

Bevacizumab

Bevacizumab will be administered at a standard dose of 15 mg/kg every 3 weeks.

DRUG

Atezolizumab

Atezolizumab will be administered intravenously a standard dose of 12,000 mg every 3 weeks.

Trial Locations (1)

33612

Moffitt Cancer Center, Tampa

Sponsors
All Listed Sponsors
collaborator

Karyopharm Therapeutics Inc

INDUSTRY

lead

H. Lee Moffitt Cancer Center and Research Institute

OTHER